FDA 510(k) vs De Novo vs PMA for medical devices
A 510(k) clears through substantial equivalence to a predicate; De Novo grants a new Class I or II classification for a novel low- or moderate-risk device without a suitable predicate; PMA approves a Class III device after the most stringent application review. Each is product- and intended-use-specific.
A 510(k) clears a device based on substantial equivalence to a legally marketed predicate; De Novo grants a new Class I or II classification for a novel low- or moderate-risk device without a suitable predicate; PMA approves a Class III device after the most stringent application review. Each decision is product- and intended-use-specific. None alone endorses a clinic, operator, superiority claim, or off-label use.1234
The three pathways should not be ranked as bronze, silver and gold. FDA applies different controls according to device type, risk and regulatory history.
Start with the pathway’s decision question
| Pathway | Core FDA question | Public record to read |
|---|---|---|
| 510(k) | Is the new device substantially equivalent to a legally marketed predicate for the stated intended use and technological characteristics, with performance information as needed? | Substantial-equivalence letter, 510(k) summary or statement, indications for use, product code and predicate |
| De Novo | Can a novel device without a suitable predicate be classified as Class I or II because general controls, or general plus special controls, provide reasonable assurance of safety and effectiveness? | Grant order, decision summary, classification regulation, special controls and indications |
| PMA | Does the application provide valid scientific evidence giving reasonable assurance that the Class III device is safe and effective for its intended use? | Approval order, Summary of Safety and Effectiveness Data, labeling, conditions, supplements and post-approval studies |
Most Class II devices that require premarket review use 510(k), while lower-risk exempt devices may not need that submission. De Novo creates a new Class I or II device type when no legally marketed predicate fits; a granted De Novo can later serve as a predicate for appropriate 510(k)s.123 PMA is generally the pathway for Class III devices and uses the most stringent application review.14
“Cleared” and “approved” preserve useful information
FDA issues a substantial-equivalence order that clears a 510(k). FDA grants a De Novo classification request, authorizing marketing and creating a classification. FDA approves a PMA.234 “FDA authorized” can be a broad accurate umbrella when the exact pathway is stated nearby, but it should not erase the more informative verb.
The FDA-status vocabulary guide also separates establishment registration, device listing, drug approval, authorization and off-label use. A number starting with K, DEN or P means little without the document and identity match.
Read a 510(k) beyond the predicate name
A predicate is not merely a device that looks similar. The submission addresses intended use, technological characteristics and performance; differences may require supporting data.2 Open the indications-for-use page and summary. Record:
- applicant and proprietary device name;
- K number and decision date;
- product code and regulation;
- prescription or over-the-counter status;
- intended use, population, anatomy and endpoint;
- hardware, software, handpieces and accessories;
- predicate or predicates;
- bench, biocompatibility, electrical, software or clinical information summarized; and
- limitations, warnings and later changes.
“Same predicate as” does not mean clinically identical, equally effective for every purpose, or approved through PMA.
Read a De Novo as both authorization and rulemaking
A De Novo grant authorizes the submitted device and establishes a device type in Class I or II with applicable controls.3 The decision summary can explain risks, mitigations, performance and special controls. The resulting product code and classification help define what later 510(k) devices must address.
This makes the chronology important: the De Novo device may be the first authorized device of its type, while later products cite it as a predicate. “Novel” describes the absence of an appropriate predicate at that regulatory stage; it does not prove clinical superiority.
Read a PMA with its supplements
PMA records can include an approval order, detailed Summary of Safety and Effectiveness Data, professional and patient labeling, restrictions, conditions of approval, post-approval studies and later supplements.45 A supplement can change labeling, design, manufacturing, indication, software or other aspects. The original PMA number alone may not describe the current product or use.
When a clinic cites a PMA, match the supplement and labeling version supporting the advertised indication. Do not apply a PMA for one product in a filler or implant family to every related product.
Verify the service after the device
The FDA decision does not license the operator, inspect the treatment quality of a particular clinic, set every protocol, or guarantee an outcome. After matching the device, verify professional license, facility, training, prescription, maintenance, settings, contraindications, consent, adverse-event response and follow-up.
- Identify the physical device. Capture legal manufacturer, proprietary name, model, software, handpiece, accessories, UDI and label.
- Classify before searching. Find product code and regulation, then determine exemption or the applicable K, DEN, P or other decision record.
- Open the core documents. Read the order, indications, summary, labeling, controls, supplements and current safety records.
- Match the advertised use. Compare population, anatomy, purpose, endpoint, setting, prescription status, operator and configuration.
- Test extra claims separately. Require evidence for superiority, magnitude, duration, comfort, recovery or off-label use rather than borrowing the pathway.
The decisive question is: “Which exact FDA pathway and decision document covers this device configuration and intended use, and which parts of the clinic’s claim go beyond it?”
Sources
- U.S. Food and Drug Administration. Medical Device Safety and the 510(k) Clearance Process. Used for FDA's current high-level comparison of PMA, De Novo, and 510(k) by risk and predicate. Accessed .
- U.S. Food and Drug Administration. Premarket Notification 510(k). Used for substantial equivalence, predicate, clearance order, exemptions, and change boundaries. Accessed .
- U.S. Food and Drug Administration. De Novo Classification Request. Used for the novel low- or moderate-risk classification pathway and future-predicate effect. Accessed .
- U.S. Food and Drug Administration. Premarket Approval (PMA). Used for the Class III PMA standard, application, approval, supplements, and decision records. Accessed .
- U.S. Food and Drug Administration. Device Approvals and Clearances. Used for decision-database scope and the distinction among pathway documents. Accessed .